New hope for hunter syndrome: Long-Term drug trial launches
NCT ID NCT06075537
First seen Sep 30, 2025 · Last updated May 07, 2026 · Updated 32 times
Summary
This study looks at the long-term safety and effects of an experimental drug called DNL310 for people with Hunter syndrome (MPS II), a rare genetic disease. About 99 participants who finished earlier studies will receive the drug for up to 5 years. The goal is to see if the drug remains safe and helps control the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOPOLYSACCHARIDOSIS II are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST di Cremona
Cremona, Italy
-
Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia
Udine, Italy
-
Birmingham Women's and Children's NHS Foundation Trust
Birmingham, United Kingdom
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, 45229, United States
-
Drottning Silvias Barn Och Ungdomssjukhus
Gothenburg, Sweden
-
Erasmus Medical Center - Sophia Children's Hospital
Rotterdam, 3015 GD, Netherlands
-
Gazi Universitesi Tip Fakultes
Ankara, Turkey (Türkiye)
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Hopital Jeanne De Flandre - Metabolic Diseases Unit
Lille, France
-
Hospit U. Vall d'Hebron - PPDS
Barcelona, Spain
-
Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
-
Huntsman Cancer Hospital
Salt Lake City, Utah, 84112, United States
-
McGill University Health Center
Montreal, Quebec, H4A3J1, Canada
-
Royal Free Hospital
London, NW3 2QG, United Kingdom
-
Sanatorio Mater Dei
Buenos Aires, Argentina
-
SpinCS GmbH
Höchheim, Germany
-
The University of Texas Medical School at Houston
Houston, Texas, 77030, United States
-
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609, United States
-
UNC Children's Research Institute
Chapel Hill, North Carolina, 27599, United States
-
UZ Brussel
Jette, Belgium
-
Universitair Ziekenhuis Antwerpen
Edegem, Antwerpen, 2650, Belgium
-
University Medical Faculty Balcali Hospital
Adana, Turkey (Türkiye)
-
University of Alberta - Faculty of Medicine & Dentistry
Edmonton, Alberta, Canada
-
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
-
Vseobecna Fakultni Nemocnice V Praze
Prague, 120 00, Czechia
Conditions
Explore the condition pages connected to this study.